SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 2,178.12 |
| Enterprise Value ($M) | 2,927.75 |
| Book Value ($M) | 2,669.07 |
| Book Value / Share | 12.30 |
| Price / Book | 0.82 |
| NCAV ($M) | -814.58 |
| NCAV / Share | -3.75 |
| Price / NCAV | -2.67 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.13 |
| Return on Assets (ROA) | -0.10 |
| Return on Equity (ROE) | -0.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.46 |
| Current Ratio | 3.77 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 570.45 |
| Assets | 4,054.09 |
| Liabilities | 1,385.02 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 924.22 |
| Operating Income | 58.66 |
| Net Income | -9.42 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 35.26 |
| Cash from Investing | -29.31 |
| Cash from Financing | 1.92 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Select Equity Group, L.P. | |||
| 13G/A | Baillie Gifford & Co | |||
| 13G | William Blair Investment Management, Llc | 6.10 | ||
| 13G/A | Vanguard Group Inc | 9.04 | 2.57 | |
| 13G/A | Wasatch Advisors Inc | |||
| 13G/A | Norges Bank | 8.41 | -1.26 | |
| 13G/A | BlackRock, Inc. | 11.50 | 1.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 298,152 | 1,152,621 | 25.87 | |
| 595,252 | 1,588,527 | 37.47 | |
| 716,174 | 2,122,730 | 33.74 | |
| 575,706 | 1,820,162 | 31.63 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MRVI – Maravai LifeSciences Holdings, Inc. | MYGN – Myriad Genetics, Inc. |
| NBIX – Neurocrine Biosciences, Inc. | NKTX – Nkarta, Inc. |
| NMRA – Neumora Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io